| Ytd | -85.23% | |
| 1y | -89.06% |
| Open | 4.52 | Prev Close | 4.53 | Low | 4.21 | High | 4.72 | Mkt Cap | 1.39M |
| Vol | 34.13K | Avg Vol | 858.56K | EPS | -7.96 | P/E | -0.56 | Forward P/E | -0.03 |
| Beta | 2.57 | Short Ratio | 1.07 | Inst. Own | 11.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 5.92 | 200-d Avg | 16.29 | 1yr Est | 3.00 |
ERNA News
Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 year
CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-1
Ernexa Therapeutics Inc. (NASDAQ:ERNA) on Wednesday said an independently conducted preclinical stud
Ernexa Therapeutics reports independent preclinical validation of ERNA-101 with PD-1 therapy ahead o
US stocks traded higher with Dow up 150 points. Consumer discretionary shares surged 1.3% while heal
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the tre
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Signi
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune
New platform provides additional perspective on Ernexa's mission to deliver hope for patients throug
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical O
Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engin
CAMBRIDGE, Mass. , May 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry
Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-
Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to addr
Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are skyrocketing Tuesday. The market is seemingly react
US stocks lower, Nasdaq down 1% on Tuesday. Health care shares rise 1.7%. Inflation climbs to 3.8%,
Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving
CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry i
CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101
Ernexa Therapeutics Inc. (NASDAQ: ERNA - Get Free Report) saw a significant growth in short interest
Ernexa Therapeutics (NASDAQ: ERNA - Get Free Report) and Aditxt (NASDAQ: ADTX - Get Free Report) are
